Inventor · disambiguated record
Caroline Mary
Also filed as: MARY CAROLINE
21 granted patents·20 pending applications·55 citations·filing 2010–2025
92Inventor score
Top patents by PatentIndex Score
41 records- 0190US8785604B2Anti-CD28 humanized antibodiesMARY CAROLINE·Filed 2011·Granted Jul 22, 2014·29 cites·14 claims
- 0287US11279766B2Anti-SIRPa antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Mar 22, 2022·3 cites·47 claims
- 0382US10364287B2Anti-CD28 humanized antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2016·Granted Jul 30, 2019·3 cites·14 claims
- 0481US11352430B2Humanized anti-human-PD-1 antibody and its use in cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Jun 7, 2022·2 cites·15 claims
- 0581US10428152B2Antibodies directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2015·Granted Oct 1, 2019·3 cites·11 claims
- 0680US12371502B2Antibodies directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jul 29, 2025·0 cites·21 claims
- 0780US11440964B2Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibodyOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Sep 13, 2022·2 cites·17 claims
- 0880US11230602B2Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Jan 25, 2022·2 cites·28 claims
- 0979US2024352135A1Antibodies and polypeptides directed against cd127OSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 1078US11098128B2Antibodies and polypeptides directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Aug 24, 2021·1 cites·26 claims
- 1176US12252546B2Anti-SIRPa antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Mar 18, 2025·0 cites·23 claims
- 1276US9562098B2Anti-CD28 humanized antibodiesEFFIMUNE·Filed 2014·Granted Feb 7, 2017·3 cites·12 claims
- 1376US9447182B2Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidatesEFFIMUNE·Filed 2012·Granted Sep 20, 2016·6 cites·13 claims
- 1474US2025215108A1ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONSOSE IMMUNOTHERAPEUTICS·Filed 2025·Application pending·0 cites
- 1572US11926671B2Antibodies and polypeptides directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2021·Granted Mar 12, 2024·0 cites·17 claims
- 1670US12331118B2Humanized anti-human-PD-1 antibody and methods of using them for cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jun 17, 2025·0 cites·9 claims
- 1770US2024400698A1Anti-chemokin like receptor 1 antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 1869US12331115B2Uses of anti-SIRPg antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jun 17, 2025·0 cites·3 claims
- 1963US2025250354A1New class of molecules for selective clearance of antibodyOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 2061US2025340632A1SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIESOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2159US9587023B2Recombinant monovalent antibodiesVANHOVE BERNARD·Filed 2010·Granted Mar 7, 2017·1 cites·7 claims
- 2257US2025026839A1Identification of CLEC-1 Ligand and Uses ThereofOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2357US2023227565A1Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 AgentOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2455US12448454B2Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereofOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Oct 21, 2025·0 cites·18 claims
- 2555US2024182571A1New scaffold for bifunctional molecules with improved propertiesOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2655US2024182572A1Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domainsOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2754US2024067727A1Bifunctional anti-pd1/il-7 moleculesOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 2852US2021147558A1Anti-chemokin like receptor 1 antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 2951US11713356B2Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancerOSE IMMUNOTHERAPEUTICS·Filed 2018·Granted Aug 1, 2023·0 cites·34 claims
- 3050US2022056135A1Bifunctional anti-pd-1/sirpa moleculeOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 3150US2023181721A1Vaccine against sars-cov virusOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 3250US2023331852A1Anti-clec-1a antibodies and antigen-binding fragment thereofOSE IMMUNOTHERAPEUTICS·Filed 2020·Application pending·0 cites
- 3349US2022389104A1Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 AgentOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 3449US2023303648A1Bifunctional molecules comprising an il-7 variantOSE IMMUNOTHERAPEUTICS·Filed 2020·Application pending·0 cites
- 3547US11884723B2Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Jan 30, 2024·0 cites·20 claims
- 3647US10689444B2Recombinant monovalent antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Jun 23, 2020·0 cites·11 claims
- 3747US2019382483A1NEW USES OF ANTI-SIRPg ANTIBODIESOSE IMMUNOTHERAPEUTICS·Filed 2018·Application pending·0 cites
- 3847US2023242640A1ANTI-SIRPg CompoundsOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 3946US2023071889A1Bifunctional anti-pd-1/il-7 moleculeOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 4042US2022025050A1Bifunctional molecule directed against human pd-1OSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 4133US8785138B2Monovalent ligands of the human CD28 receptorVANHOVE BERNARD·Filed 2010·Granted Jul 22, 2014·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Caroline Mary files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →